Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yao-Yu Hsieh

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
American Journal of Cancer Research|September 21, 2016
EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cellsYao-Yu Hsieh, Hsiang-Ling Lo, Pei-Ming Yang
Pathology, Research and Practice|March 16, 2019
In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinomaYao-Yu Hsieh, Tsang-Pai Liu, Pei-Ming Yang
Journal of Personalized Medicine|September 19, 2020
Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the <i>KRAS</i> (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene SignatureLi-Wei Liu, Yao-Yu Hsieh, Pei-Ming Yang
Molecular Oncology|October 16, 2023
Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistanceYao-Yu Hsieh, Jia-Ling Du, Pei-Ming Yang
International Journal of Molecular Sciences|June 24, 2022
Long Non-Coding RNA <i>MIR31HG</i> Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma CellsChing-Chung Ko, Yao-Yu Hsieh, Pei-Ming Yang
Toxicology and Applied Pharmacology|June 20, 2022
Repurposing of ingenol mebutate for treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4)Yao-Yu Hsieh, Ya-Wen Cheng, Po-Li Wei, et al.
Royal Society Open Science|December 20, 2018
Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database miningTsang-Pai Liu, Yao-Yu Hsieh, Chia-Jung Chou, et al.
International Journal of Cancer|December 20, 2019
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in TaiwanYao-Yu Hsieh, Wei-Tse Fang, Yu-Wen Lo, et al.
Biomolecules|April 25, 2020
Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent MannerPei-Ming Yang, Yao-Yu Hsieh, Jia-Ling Du, et al.
Cancer Science|February 11, 2012
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapyYao-Yu Hsieh, Cheng-Hwai Tzeng, Ming-Huang Chen, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
American Journal of Cancer Research|September 21, 2016
EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cellsYao-Yu Hsieh, Hsiang-Ling Lo, Pei-Ming Yang
Pathology, Research and Practice|March 16, 2019
In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinomaYao-Yu Hsieh, Tsang-Pai Liu, Pei-Ming Yang
Journal of Personalized Medicine|September 19, 2020
Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the <i>KRAS</i> (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene SignatureLi-Wei Liu, Yao-Yu Hsieh, Pei-Ming Yang
Molecular Oncology|October 16, 2023
Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistanceYao-Yu Hsieh, Jia-Ling Du, Pei-Ming Yang
International Journal of Molecular Sciences|June 24, 2022
Long Non-Coding RNA <i>MIR31HG</i> Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma CellsChing-Chung Ko, Yao-Yu Hsieh, Pei-Ming Yang
Toxicology and Applied Pharmacology|June 20, 2022
Repurposing of ingenol mebutate for treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4)Yao-Yu Hsieh, Ya-Wen Cheng, Po-Li Wei, et al.
Royal Society Open Science|December 20, 2018
Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database miningTsang-Pai Liu, Yao-Yu Hsieh, Chia-Jung Chou, et al.
International Journal of Cancer|December 20, 2019
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in TaiwanYao-Yu Hsieh, Wei-Tse Fang, Yu-Wen Lo, et al.
Biomolecules|April 25, 2020
Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent MannerPei-Ming Yang, Yao-Yu Hsieh, Jia-Ling Du, et al.
Cancer Science|February 11, 2012
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapyYao-Yu Hsieh, Cheng-Hwai Tzeng, Ming-Huang Chen, et al.
Pageof 5